Company: TAK
Filing Date: 2025-06-25
Form Type: 20-F
Source: 0001395064-25-000095
Chunk: 57

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-06-25
Form: 20-F
Item: Item 4
Chunk 57
---
 the standard of care for people living with rare sleep-wake disorders and other conditions where orexin biology is implicated. Across our portfolio, we are harnessing advances in disease biology understanding, translational tools, innovative modalities and digital innovation to accelerate development and patient access.

Our neuroscience pipeline in clinical development as of May 8, 2025 (the date of our annual earnings release), along with notes for major subsequent developments thereafter, is as follows:

  Development code        Type of Drug                                                Modality                Indications / additional formulations      Country/Region      Stage  
  TAK-861                 Orexin 2R agonist (oral)                                    Small molecule          Narcolepsy type 1                          Global              P-III  
  TAK-341/MEDI1341 1      Alpha-synuclein antibody (injection)                        Biologic and other      Multiple System Atrophy (MSA)              -                   P-II   
  TAK-594/DNL593 2        Brain-penetrant progranulin fusion protein (injection)      Biologic and other      Frontotemporal dementia                    -                   P-II   
  TAK-360                 Orexin 2R agonist (oral)                                    Small molecule          Idiopathic hypersomnia                     -                   P-II   
                                                                                                              Narcolepsy type 2                          -                   P-I    
  TAK-925                 Orexin 2R agonist (injection)                               Small molecule          Narcolepsy                                 -                   P-I    

____________

Notes:

(1) Partnership with Alexion, a subsidiary of AstraZeneca.

(2) Partnership with Denali Therapeutics. Denali leads development.

Table of Contents

Oncology

In oncology, we are committed to ensuring that patients globally can benefit from and access our portfolio of medicines, while also making progress on a pipeline of potential treatments for the future. Our research and development efforts are focused on three disease areas and four modalities. We are advancing medicines for thoracic, gastrointestinal and hematologic cancers. Within hematologic cancers, we are growing a portfolio of medicines for myeloid cancers, including rusfertide (TAK-121) and elritercept (TAK-226). Our core modalities include antibody drug conjugates (ADCs), complex biologics, small molecules and gamma delta T cell therapies. We complement our internal expertise and global footprint with a robust network of collaborators. We aspire to cure cancer, with inspiration from patients and innovation from everywhere.